1. Home
  2. ABEO vs TEI Comparison

ABEO vs TEI Comparison

Compare ABEO & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • TEI
  • Stock Information
  • Founded
  • ABEO 1974
  • TEI 1993
  • Country
  • ABEO United States
  • TEI United States
  • Employees
  • ABEO N/A
  • TEI N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • TEI Finance Companies
  • Sector
  • ABEO Health Care
  • TEI Finance
  • Exchange
  • ABEO Nasdaq
  • TEI Nasdaq
  • Market Cap
  • ABEO 350.2M
  • TEI 282.9M
  • IPO Year
  • ABEO 1980
  • TEI N/A
  • Fundamental
  • Price
  • ABEO $6.88
  • TEI $6.12
  • Analyst Decision
  • ABEO Strong Buy
  • TEI
  • Analyst Count
  • ABEO 6
  • TEI 0
  • Target Price
  • ABEO $18.17
  • TEI N/A
  • AVG Volume (30 Days)
  • ABEO 687.8K
  • TEI 142.4K
  • Earning Date
  • ABEO 08-14-2025
  • TEI 01-01-0001
  • Dividend Yield
  • ABEO N/A
  • TEI 10.51%
  • EPS Growth
  • ABEO N/A
  • TEI N/A
  • EPS
  • ABEO 0.99
  • TEI N/A
  • Revenue
  • ABEO $400,000.00
  • TEI N/A
  • Revenue This Year
  • ABEO N/A
  • TEI N/A
  • Revenue Next Year
  • ABEO $339.63
  • TEI N/A
  • P/E Ratio
  • ABEO $7.02
  • TEI N/A
  • Revenue Growth
  • ABEO N/A
  • TEI N/A
  • 52 Week Low
  • ABEO $3.93
  • TEI $4.35
  • 52 Week High
  • ABEO $7.54
  • TEI $5.39
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 56.13
  • TEI 59.97
  • Support Level
  • ABEO $6.74
  • TEI $6.07
  • Resistance Level
  • ABEO $7.05
  • TEI $6.19
  • Average True Range (ATR)
  • ABEO 0.26
  • TEI 0.06
  • MACD
  • ABEO -0.03
  • TEI 0.00
  • Stochastic Oscillator
  • ABEO 30.95
  • TEI 79.17

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

About TEI Templeton Emerging Markets Income Fund Inc.

Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.

Share on Social Networks: